Prima BioMed (PBMD) Immunotherapy Delivery Method Looks Promising - Maxim Group
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St set to gain on tech rebound, Middle East in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Alibaba falls on China AI capex report; Citi says selloff is premature
FBR Capital Remains Bullish as Prima BioMed (PBMD) Announces Investigator-Sponsored Trial
July 12, 2016 1:47 PM EDTFBR Capital reiterated an Outperform rating and $6.00 price target on Prima Biomed (NASDAQ: PBMD) following the company's announced collaboration for an investigator-sponsored clinical trial.
Analyst Vernon Bernardino commented, "Earlier today, July 12, Prima BioMed (PBMD) announced a new collaboration for an investigatorsponsored clinical trial named INSIGHT to evaluate intra-tumoral injection of PBMDs immune-oncology therapy,... More
